Dayang Bio (003017.SZ): Possesses pilot-scale production technology for the PEEK intermediate fluoroketone, as well as production capacity for fluorobenzene, a key raw material for fluoroketone.

Gelonghui, May 28 — Ocean Biochemical (003017.SZ) stated on an interactive platform that the company possesses pilot-scale technology for producing fluoroketone, an intermediate for PEEK, as well as production capacity for fluorobenzene, a key raw material for fluoroketone. As a chemical raw material/material production project, the required preliminary permits and filing procedures are time-consuming, and the project remains in the early preparation stage.

Gelonghui FinanceMay 28 15:30

Dayang Bio (003017.SZ): Has not yet offered electronic-grade potassium carbonate products for sale.

Gelonghui, May 28 — Dayang Bio (003017.SZ) stated on an interactive platform that its potassium carbonate products are currently primarily used in general industrial applications such as pesticides, pharmaceuticals, ceramics, and glass manufacturing, and it does not yet offer electronic-grade potassium carbonate for sale. The company will closely monitor market demand dynamics and industry technology trends. Investors are advised to pay attention to investment risks.

Gelonghui FinanceMay 28 15:29

Dayang Bio (003017.SZ): A party acting in concert with the actual controller intends to reduce holdings by no more than 0.63% of shares.

Gelonghui, May 19 — Ocean Biochemical (003017.SZ) announced that Mr. Qian Jianchun, Mr. Chen Shouliang, and Ms. Zhao Yumei, who are acting in concert with the company’s actual controller Mr. Chen Yanggui, intend to collectively sell no more than 534,700 shares of the company (inclusive) through centralized bidding transactions within three consecutive months following the expiration of 15 trading days from the date of disclosure of this share reduction plan announcement (i.e., from June 10, 2026, to September 9, 2026, excluding any periods during which share sales are prohibited under regulations issued by the China Securities Regulatory Commission or the Shenzhen Stock Exchange). This amount represents no more than

Gelonghui FinanceMay 19 20:13

Dayang Bio (003017): Q1 performance shows year-on-year and quarter-on-quarter growth; industrial chain layout is gradually improving.

Q1 performance showed both year-over-year and quarter-over-quarter growth. Long-term growth prospects for the company remain positive, and we maintain a 'Buy' rating. The company released its 2025 annual report and Q1 2026 earnings report, achieving revenue of 1.045 billion yuan in 2025, representing a year-over-year increase of 14.89%.

Open Source SecuritiesApr 28 19:46

Dayang Bio's net profit in 2025 reached 99.8544 million yuan, increasing by 56.64%. The cost advantage of potassium chloride drove the profitability quality of its core business.

In 2025, the company's revenue reached RMB 1.045 billion (+14.89%), with a net profit attributable to parent company shareholders of RMB 99.8544 million (+56.64%) and a non-recurring net profit of RMB 92.754 million (+51.64%). The growth rate of profitability was significantly higher than that of revenue, with a substantial improvement in main business cash flow. Inorganic salts and fine chemicals accounted for 93.63% of total revenue, reflecting an increase in the concentration of core businesses. R&D investment increased by 52.09%, roughly in line with the growth in profitability. Progress on fundraising projects showed divergence, with some delays, while capital operations and dividend plans proceeded steadily.

lanjinger.comApr 28 16:18

Dayang Bio: 2025 Annual Report

SZSIApr 28 00:00 · Announcements